Edoxaban

ApprovedCompleted

1 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Atrial Fibrillation

Conditions

Atrial Fibrillation, Left Atrial Appendage Thrombosis

Trial Timeline

May 19, 2019 → Aug 1, 2024

NCT ID

NCT03840291

About Edoxaban

Edoxaban is a approved stage product being developed by Daiichi Sankyo for Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT03840291. Target conditions include Atrial Fibrillation, Left Atrial Appendage Thrombosis.

What happened to similar drugs?

20 of 20 similar drugs in Atrial Fibrillation were approved

Approved (20) Terminated (4) Active (0)

✅OAC aloneDaiichi SankyoApproved

✅Edoxaban + Aspirin and Clopidogrel + Aspirin and WarfarinDaiichi SankyoApproved

✅dapagliflozin + PlaceboAstraZenecaApproved

✅valsartanNovartisApproved

✅Apixaban + Parenteral heparin and/or oral Vitamin K antagonistPfizerApproved

✅Vitamin K antagonist + ApixabanPfizerApproved

✅Apixaban + aspirinPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05804747	Pre-clinical	Completed	Feb 16, 2023	Jul 28, 2025	Atrial Fibrillation
NCT04747496	Pre-clinical	Completed	Feb 26, 2021	Nov 27, 2024	Non-valvular Atrial Fibrillation
NCT04594915	Pre-clinical	Completed	Aug 14, 2020	Jun 21, 2023	Atrial Fibrillation
NCT04519944	Pre-clinical	Completed	Jun 30, 2020	Jul 6, 2023	Non-valvular Atrial Fibrillation
NCT04171726	Phase 3	UNKNOWN	Aug 1, 2019	Sep 1, 2023	Aortic Valve Stenosis
NCT03840291	Approved	Completed	May 19, 2019	Aug 1, 2024	Atrial Fibrillation
NCT03247569	Pre-clinical	Completed	Oct 18, 2017	Feb 28, 2022	Atrial Fibrillation
NCT03247582	Pre-clinical	Completed	Aug 2, 2017	May 3, 2022	Atrial Fibrillation
NCT02952599	Pre-clinical	Completed	Mar 27, 2017	Oct 29, 2019	Venous Thromboembolism
NCT02951039	Pre-clinical	Completed	Feb 21, 2017	Oct 15, 2020	Atrial Fibrillation
NCT02964949	Pre-clinical	Completed	Jan 24, 2017	Oct 9, 2018	Atrial Fibrillation
NCT02943993	Pre-clinical	Completed	Apr 6, 2016	Dec 1, 2020	Venous Thromboembolism
NCT02944019	Pre-clinical	Completed	Aug 1, 2015	Apr 13, 2022	Atrial Fibrillation
NCT02448901	Pre-clinical	UNKNOWN	Apr 1, 2015	Mar 1, 2016	Heart Failure

Competing Products

20 competing products in Atrial Fibrillation

See all competitors

Product	Company	Stage	Hype Score
Edoxaban	Daiichi Sankyo	Pre-clinical	26
Edoxaban + Clopidogrel + Prasugrel + Ticagrelor + Vitamin K antagonist	Daiichi Sankyo	Phase 3	40
OAC alone	Daiichi Sankyo	Approved	43
Edoxaban + ASA	Daiichi Sankyo	Phase 3	32
DU-176b tablets + DU-176b tablets + Warfarin tablets	Daiichi Sankyo	Phase 2	35
Edoxaban + Apixaban + Rivaroxaban	Daiichi Sankyo	Pre-clinical	26
Edoxaban + VKA-Based Regimen + VKA-Based Regimen + VKA-Based Regimen + VKA-Based Regimen	Daiichi Sankyo	Phase 3	40
Edoxaban (DU-176b) + Edoxaban (DU-176b) + Edoxaban (DU-176b) + Edoxaban (DU-176b) + warfarin	Daiichi Sankyo	Phase 2	35
Edoxaban	Daiichi Sankyo	Pre-clinical	26
Edoxaban + Warfarin + Enoxaparin	Daiichi Sankyo	Phase 3	40
Edoxaban	Daiichi Sankyo	Pre-clinical	26
Edoxaban	Daiichi Sankyo	Pre-clinical	26
DU-176b 15mg + DU-176b 30mg + DU-176b 60mg	Daiichi Sankyo	Phase 3	40
dabigatran, rivaroxaban, apixaban or edoxaban	Daiichi Sankyo	Pre-clinical	22
Edoxaban	Daiichi Sankyo	Pre-clinical	26
DU-176b tablets + Warfarin potassium tablets	Daiichi Sankyo	Phase 2	35
Edoxaban-based Regimen + VKA-based Regimen	Daiichi Sankyo	Phase 3	40
Edoxaban	Daiichi Sankyo	Pre-clinical	26
Edoxaban + Aspirin and Clopidogrel + Aspirin and Warfarin	Daiichi Sankyo	Approved	39
Edoxaban	Daiichi Sankyo	Pre-clinical	26